Arthralgia Management Market Snapshot (2023 to 2033)

The global arthralgia management market garnered a market value of US$ 5.95 billion in 2022 and is expected to accumulate a market value of US$ 15.5 billion by registering a CAGR of 9.1% in the forecast period 2023 to 2033. Growth of the arthralgia management market can be attributed to increasing number of individuals are looking for efficient remedies to manage this ailment. The market for arthralgia management registered a CAGR of 5.3% in the historical period 2018 to 2022

Arthralgia management refers to the medical care and treatment provided to individuals experiencing joint pain or arthralgia. Arthralgia is a common symptom of many different conditions, including arthritis, lupus, fibromyalgia, and other autoimmune diseases.

Report Attribute Details
Expected Market Value (2023) US$ 6.49 billion
Anticipated Forecast Value (2033) US$ 15.5 billion
Projected Growth Rate (2023 to 2033) 9.1% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Arthralgia Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Arthralgia management reflected a value of 5.3% during the historical period, 2018 to 2022. The growth of the arthralgia management market is being driven by several factors, including the increasing prevalence of arthritis and related conditions, the aging population, rising healthcare expenditure, and advancements in medical technology. In addition, there is growing awareness about joint health and the importance of managing arthralgia symptoms, which is also contributing to market growth.

The market for arthralgia management products and services is diverse and includes a wide range of products, such as prescription medications, over-the-counter pain relievers, topical creams, supplements, and medical devices. In addition, there is a growing trend towards holistic and alternative therapies such as acupuncture, chiropractic, and massage therapy. Thus, the market for arthralgia management is expected to register a CAGR of 9.1% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Arthralgia Management Market?

Advancements in arthralgia management products spurring market growth for Arthralgia management

Arthritis is a common cause of joint pain, and its prevalence is increasing worldwide due to aging populations, unhealthy lifestyles, and other factors. As a result, the demand for arthralgia management products and services is also increasing.

Many people are becoming more aware of the importance of joint health and are taking proactive steps to manage joint pain. This includes regular exercise, a healthy diet, and the use of arthralgia management products such as supplements, pain relievers, and topical creams.

The development of new and more effective arthralgia management products is driving growth in the market. This includes novel drug therapies, innovative medical devices, and advanced diagnostic tools. As healthcare spending continues to rise globally, more resources are being allocated to the management of chronic conditions such as arthritis. This has led to increased investment in research and development of arthralgia management products and services.

As the global population ages, the incidence of joint pain and related conditions such as arthritis is expected to increase. This is driving demand for arthralgia management products and services tailored to the needs of older adults.

Availability of treatment options shaping landscape for arthralgia management market

Medication: Nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids may be prescribed to relieve joint pain and inflammation. Disease-modifying antirheumatic drugs (DMARDs) may also be used to treat underlying autoimmune conditions.

Lifestyle modifications: Exercise, physical therapy, and weight management may be recommended to improve joint flexibility, reduce pain, and prevent further joint damage.

Alternative therapies: Acupuncture, massage therapy, and dietary supplements may be used to complement traditional medical treatment.

Surgical intervention: In severe cases, surgery may be necessary to repair damaged joints or replace them with artificial joints.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Arthralgia Management Market?

Lack of awareness and challenges with regulatory approvals derailing market growth for arthralgia management market

Many of the current treatments for arthralgia, such as nonsteroidal anti-inflammatory drugs (NSAIDs), have limited efficacy and can have side effects. This has led to a need for more effective and safer treatments. Arthralgia management products and services can be expensive, particularly for those without insurance coverage. This can limit access to treatment for some patients.

While awareness about joint health is increasing, there is still a lack of awareness among many individuals about the available treatment options for arthralgia. This can lead to delayed diagnosis and treatment. Developing new arthralgia management products and bringing them to market can be a lengthy and costly process due to regulatory requirements. This can limit innovation in the industry.

Many individuals with arthralgia seek alternative therapies such as acupuncture, chiropractic, or herbal remedies. This can limit demand for traditional arthralgia management products and services.

Region-Wise Insights

Geriatric Population Driving Growth of Arthralgia Management Market in North America?

Advancements in medical technology driving growth of Arthralgia management market

The arthralgia management market in North America is expected to continue to grow in the coming years. North America has a high prevalence of arthralgia and related conditions such as arthritis, and this is driving demand for arthralgia management products and services in the region.

The United States is the largest market for arthralgia management in North America, accounting for the majority of the region's market share. The market is also growing in Canada and Mexico, although at a slower pace than in the United States.

Some of the key drivers of the arthralgia management market in North America include the aging population, rising healthcare expenditure, and advancements in medical technology. In addition, there is increasing awareness about joint health and the importance of managing arthralgia symptoms.

The market for arthralgia management products and services in North America is diverse and includes a wide range of products, such as prescription medications, over-the-counter pain relievers, topical creams, supplements, and medical devices. In addition, there is a growing trend towards holistic and alternative therapies such as acupuncture, chiropractic, and massage therapy. Thus, owing to the aforementioned reasons, North America is expected to hold 43% market share for arthralgia management market in 2023.

Growing Trend Towards Holistic and Alternative Therapies Bolstering Growth for Arthralgia Management Market in Europe?

High prevalence of arthritis boosting arthralgia management market growth in Europe

The arthralgia management market in Europe is also expected to continue to grow in the coming years. Europe has a high prevalence of arthritis and related conditions, and this is driving demand for arthralgia management products and services in the region.

The market for arthralgia management in Europe is diverse and includes a wide range of products, such as prescription medications, over-the-counter pain relievers, topical creams, supplements, and medical devices. In addition, there is a growing trend towards holistic and alternative therapies such as acupuncture, chiropractic, and massage therapy.

The United Kingdom, Germany, France, Italy, and Spain are the largest markets for arthralgia management in Europe, accounting for the majority of the region's market share. The market is also growing in other European countries, although at a slower pace than in these major markets. Thus, Europe is expected to hold 41% market share for arthralgia management market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Availability of NSAIDs in various formulations Making it Popular for Arthralgia Management?

Effective nature of NSAIDs increasing dependency for management of arthralgia

NSAIDs are often used for arthralgia management because they are effective at reducing pain, inflammation, and fever. They work by inhibiting the production of prostaglandins, which are responsible for causing inflammation and pain in the body. NSAIDs are widely available and can be purchased over-the-counter, making them a convenient option for many patients.

Additionally, NSAIDs are generally well-tolerated by most patients when taken as directed. They are available in a variety of formulations, including oral tablets, capsules, and liquids, as well as topical creams and gels that can be applied directly to the affected joint. This makes it easier for patients to find a formulation that works well for them. Thus, by drug class, NSAIDs are expected to possess 40% market share for arthralgia management market in 2023.

Market Competition

Key players in the arthralgia management market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Boehringer Ingelheim International GmbH, AstraZeneca, Johnson & Johnson Private Limited, Merck & Co., Inc., Hoffmann-La Roche Ltd. and Bristol-Myers Squibb Company

  • Pfizer Inc. has developed the most well-known drugs developed by Pfizer for arthralgia management is Celebrex (celecoxib). Celebrex is a type of NSAID known as a COX-2 inhibitor, which works by selectively blocking the COX-2 enzyme responsible for inflammation and pain in the body. It is commonly used to treat osteoarthritis, rheumatoid arthritis, and other types of joint pain. Celebrex is available by prescription only and is marketed by Pfizer.
  • GlaxoSmithKline (GSK) Plc. has developed Voltaren (diclofenac sodium). Voltaren is a nonsteroidal anti-inflammatory drug (NSAID) that is used to reduce pain, inflammation, and stiffness in joints caused by conditions such as osteoarthritis and rheumatoid arthritis. Voltaren is available in various formulations, including tablets, capsules, and gels.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 6.49 billion
Market Value in 2033 US$ 15.5 billion
Growth Rate CAGR of 9.1% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Class
  • Application
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
Key Companies Profiled
  • Pfizer Inc.
  • GSK Plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A
  • Boehringer Ingelheim International GmbH
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Merck & Co., Inc.
  • Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
Customization Available Upon Request

Key Segments Profiled in the Arthralgia Management Market Survey

By Drug Class:

  • NSAID
  • Corticosteroids
  • Antidepressants
  • Anticonvulsants
  • Antibiotics

By Application:

  • Knee and Ankle Pain
  • Hip Pain
  • Shoulder and Elbow Pain
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

How is the Historical Performance of the Arthralgia Management Market?

From 2018 to 2022, the market registered a CAGR of 5.3%.

How Big Will the Arthralgia Management Market Be by 2033?

The global market is estimated to reach US$ 15.5 billion by 2033.

Which Distribution Channel Holds Lucrative Opportunities?

The hospital pharmacies hold high revenue potential.

Which Countries Dominate the HSM-as-a-service Market?

The United States, Canada and Mexico dominate the global market.

What is the Growth Forecast for HSM-as-a-service Market?

The market is forecast to register a CAGR of 9.1% through 2033.

Table of Content

1. Executive Summary | Arthralgia Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. NSAID

        5.3.2. Corticosteroids

        5.3.3. Antidepressants

        5.3.4. Anticonvulsants

        5.3.5. Antibiotics

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2023 to 2033

        6.3.1. Knee and Ankle Pain

        6.3.2. Hip Pain

        6.3.3. Shoulder and Elbow Pain

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Application

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Application

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Application

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Application

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. United Kingdom

            11.2.1.2. Spain

            11.2.1.3. Germany

            11.2.1.4. Italy

            11.2.1.5. France

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Application

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Application

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. India

            12.2.1.4. South Korea

            12.2.1.5. Rest of Asia Pacific

        12.2.2. By Drug Class

        12.2.3. By Application

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Application

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. South Africa

            13.2.1.2. GCC Countries

            13.2.1.3. Rest of Middle East and Africa

        13.2.2. By Drug Class

        13.2.3. By Application

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Application

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Drug Class

            14.1.2.2. By Application

            14.1.2.3. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Drug Class

            14.2.2.2. By Application

            14.2.2.3. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Drug Class

            14.3.2.2. By Application

            14.3.2.3. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Drug Class

            14.4.2.2. By Application

            14.4.2.3. By Distribution Channel

    14.5. U.K.

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Drug Class

            14.5.2.2. By Application

            14.5.2.3. By Distribution Channel

    14.6. Spain

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Drug Class

            14.6.2.2. By Application

            14.6.2.3. By Distribution Channel

    14.7. Germany

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Drug Class

            14.7.2.2. By Application

            14.7.2.3. By Distribution Channel

    14.8. Italy

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Drug Class

            14.8.2.2. By Application

            14.8.2.3. By Distribution Channel

    14.9. France

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Drug Class

            14.9.2.2. By Application

            14.9.2.3. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Drug Class

            14.10.2.2. By Application

            14.10.2.3. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Drug Class

            14.11.2.2. By Application

            14.11.2.3. By Distribution Channel

    14.12. India

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Drug Class

            14.12.2.2. By Application

            14.12.2.3. By Distribution Channel

    14.13. South Korea

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Drug Class

            14.13.2.2. By Application

            14.13.2.3. By Distribution Channel

    14.14. South Africa

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Drug Class

            14.14.2.2. By Application

            14.14.2.3. By Distribution Channel

    14.15. GCC Countries

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Drug Class

            14.15.2.2. By Application

            14.15.2.3. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Class

        15.3.3. By Application

        15.3.4. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Pfizer Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. GlaxoSmithKline plc

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Novartis AG

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Mylan N.V.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Teva Pharmaceutical Industries Ltd.

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Sanofi

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Boehringer Ingelheim International GmbH

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. AstraZeneca

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Johnson & Johnson Private Limited

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Merck & Co., Inc.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

        16.1.11. F. Hoffmann-La Roche Ltd.

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

        16.1.12. Bristol-Myers Squibb Company

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Psoriatic Arthritis (PsA) Treatment Market

January 2022

REP-GB-2718

May 2024

315 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Arthralgia Management Market